Cargando…

Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model

BACKGROUND: A total of 11 treatment sequences for advanced wild-type squamous non-small cell lung cancer are recommended by Chinese Society of Clinical Oncology Guidelines, consisting of seven first-line and three second-line treatments. Five of these treatments were newly approved in China between...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Mingye, Shao, Taihang, Chi, Zhuoyuan, Tang, Wenxi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Public Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999022/ https://www.ncbi.nlm.nih.gov/pubmed/36908446 http://dx.doi.org/10.3389/fpubh.2023.1051484

Ejemplares similares

Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China
por: Shao, Taihang, et al.
Publicado: (2022)

Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma
por: Shao, Taihang, et al.
Publicado: (2022)

A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer
por: Shao, Taihang, et al.
Publicado: (2022)

Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis
por: Zhao, Mingye, et al.
Publicado: (2022)

Cost-effectiveness and potential budget impact of non-pharmacological interventions for early management in prehypertensive people: an economic evaluation for China
por: Liang, Leyi, et al.
Publicado: (2023)

Impact of Extrapolation Model Choices on the Structural Uncertainty in Economic Evaluations for Cancer Immunotherapy: A Case Study of Checkmate 067
por: Shao, Taihang, et al.
Publicado: (2023)

Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis
por: Zhao, Mingye, et al.
Publicado: (2022)

Estimating the cost-effectiveness threshold of advanced non-small cell lung cancer in China using mean opportunity cost and contingent valuation method
por: Peng, Qian, et al.
Publicado: (2023)

Seven‐day vonoprazan‐based triple therapy as first‐line Helicobacter pylori treatment in comparison with extended sequential therapy
por: Chiu, Yu‐Tse, et al.
Publicado: (2023)

Cost-effectiveness analysis of camrelizumab in the second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
por: Yang, Fan, et al.
Publicado: (2021)

Effects for Sequential Treatment of siAkt and Paclitaxel on Gastric Cancer Cell Lines
por: Ku, Minhee, et al.
Publicado: (2016)

The Seven Paths
por: Foundation, Anasazi
Publicado: (2013)

Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
por: Cai, Hongfu, et al.
Publicado: (2021)

Mitomycin and 5‐fluorouracil for second‐line treatment of metastatic squamous cell carcinomas of the anal canal
por: Saint, Angélique, et al.
Publicado: (2019)

Second-line treatment for renal cell cancer
por: Di Lorenzo, G, et al.
Publicado: (2012)

Second-line treatment options in hepatocellular carcinoma
por: Marino, Donatella, et al.
Publicado: (2019)

Second-line docetaxel-based chemotherapy after failure of fluorouracil-based first-line treatment for advanced esophageal squamous cell carcinoma
por: Song, Zhengbo, et al.
Publicado: (2014)

Love at second sight: Sequential dependence of facial attractiveness in an on-line dating paradigm
por: Taubert, Jessica, et al.
Publicado: (2016)

Anticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors
por: Matsumoto, Takashi, et al.
Publicado: (2021)

Is asparaginase encapsulated in erythrocytes effective as second‐line treatment in acute lymphoblastic leukaemia?
por: van der Sluis, Inge M., et al.
Publicado: (2022)

Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung
por: Lu, Shun, et al.
Publicado: (2018)

A global perspective in second‐line treatment patterns for patients with advanced esophageal squamous cell carcinoma
por: Jaffe, Dena H., et al.
Publicado: (2022)

Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients
por: Chen, You-Yi, et al.
Publicado: (2021)

Efficacy and safety of sequential versus quadruple therapy as second-line treatment for helicobacter pylori infection—A randomized controlled trial
por: Munteanu, Daniela, et al.
Publicado: (2017)

Establishment of a first-line second-line treatment model for human pulmonary adenocarcinoma
por: Wang, Lining, et al.
Publicado: (2016)

Which second line treatments after ESA failure?
por: Park, Sophie, et al.
Publicado: (2017)

Cholangiocarcinoma: the quest for a second-line systemic treatment
por: Vienot, Angélique, et al.
Publicado: (2019)

Sirolimus as a second-line treatment for Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with RAS wild-type metastatic colorectal cancer
por: Zekri, Jamal, et al.
Publicado: (2022)

From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer
por: Martín, Andrés Muñoz, et al.
Publicado: (2018)

Efficacy of Sequential Therapy as the First-Line Treatment in the Eradication of Helicobacter pylori
por: Tamene, Yonas, et al.
Publicado: (2023)

Effectiveness of Carboplatin and Paclitaxel as First- and Second-Line Treatment in 61 Patients with Metastatic Melanoma
por: Pflugfelder, Annette, et al.
Publicado: (2011)

European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain
por: Caldas, María, et al.
Publicado: (2020)

A Budget-Impact and Cost-Effectiveness Model for Second-Line Treatment of Major Depression
por: Malone, Daniel C.
Publicado: (2007)

Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era
por: Giordano, Guido, et al.
Publicado: (2021)

Second-line afatinib administration in an elderly patient with squamous cell carcinoma
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2017)

Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence
por: Sun, Maxine, et al.
Publicado: (2014)

Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?
por: Hua, Jie, et al.
Publicado: (2018)

Internal endoscopic drainage as first line or second line treatment in case of postsleeve gastrectomy fistulas
por: Gonzalez, J. M., et al.
Publicado: (2018)

Overview of First-Line and Second-Line Pharmacotherapies for Osteoarthritis with Special Focus on Intra-Articular Treatment
por: Nowaczyk, Alicja, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sq4kddle2o9bn5sloiqec61tgq